Amgen Tops Buy Zone On Positive 2026 Outlook Amid Sharpening Obesity Focus

Amgen Stock Hits Buy Zone On Positive 2026 Outlook Amid Sharpening Obesity Focus | Investor's Business DailyBREAKING: [Eli Lilly Surges As Obesity Drugs Fuel Strong Earnings, Guidance]---Amgen (AMGN) stock popped Wednesday — surging back into a buy zone — on its surprisingly upbeat 2026 guidance despite biosimilar competition for bone health drugs Prolia and Xgeva. Prolia is an osteoporosis treatment. Xgeva aims to prevent fractures and spinal cord compression in patients who have bone metastases from cance ...